BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  BIOSECURE Act

  WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow

  WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.

  October 8, 2024

   · 

  5 min read

   · 

  Ben Hargreaves
• 

  Alzheimer’s disease

  Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout

  Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington’s is ongoing, with early data expected later this year.

  October 8, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cell and gene therapy

  Cell and Gene Therapy Investment Ticks Up After Hard Few Years

  Tim Hunt, CEO of the Alliance for Regenerative Medicine, said Monday at the 2024 Cell & Gene Meeting on the Mesa that investments reached $10.9 billion in the first half of this year—outpacing 2019’s $9.8 billion total—but far below the pandemic peak.

  October 8, 2024

   · 

  4 min read

   · 

  Greg Slabodkin
• 

  Drug Development

  Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab

  On the heels of Keytruda’s success in a Phase III perioperative trial for a disease where it had previously failed to improve event-free survival, Merck touts an I&I deal with UK biotech Mestag.

  October 8, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Neurodegenerative disease

  Scholar Rock’s Shares Soar 300% After Phase III Win in Spinal Muscular Atrophy

  With Monday’s data from SAPPHIRE, Scholar Rock is building toward regulatory submissions for apitegromab in spinal muscular atrophy in the first quarter of 2025.

  October 8, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Activist Investor Starboard Carves $1B Stake in Pfizer, Enlists Former CEO for Help

  Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its COVID-19 products.

  October 8, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Patents

  Novo, Viatris Settle Ozempic Patent Row

  Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the validity of the Danish drugmaker’s semaglutide patents.

  October 8, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy

  October 8, 2024

   · 

  2 min read
• Press Releases

  Simtra BioPharma Solutions Expands Capabilities with $14M Investment in ADC Conjugation and Purification Clinical Suite

  October 8, 2024

   · 

  2 min read
• Press Releases

  Ubix Therapeutics Accepted into Johnson & Johnson Innovation – JLABS

  October 8, 2024

   · 

  1 min read